Ind-Swift Limited

INDSWFTLTD

INE788B01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-16 EDT			5-day change	1st Jan Change
23.03 ^INR	+9.98%		+11.90%	+28.80%

06-17	Ind-Swift Limited Announces Board Appointments	CI
05-14	Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Ind-Swift Ltd Appoints Mr. Subhash Chander Galhotra as an Independent Director

January 13, 2017 at 08:05 am

Ind-Swift Ltd. has appointed Mr. Subhash Chander Galhotra as an Independent Director of the company.

Latest news about Ind-Swift Limited

Ind-Swift Limited Announces Board Appointments	06-17	CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-14	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-14	CI
Ind-Swift Limited Approves Execution of Loan Facility Agreement	03-30	CI
Ind-Swift Limited Announces Cessation of Sri Prakash Sharma as Independent Director, Effective March 31, 2024	03-30	CI
Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director	03-06	CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.	23-09-24	CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories	23-09-06	MT
The Office of the Regional P.F. Commissioner -Ii Dmg Regional Office, Karnal Imposed Damages and Interests on Ind-Swift Limited	23-08-23	CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Ind-Swift Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director	22-09-22	CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Ind-Swift Launches Products in Qatar	22-06-03	MT
Ind-Swift Limited Launches Finished Dosages Products	22-06-03	CI
Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer	22-05-30	CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Ind-Swift Forms New Subsidiary in Kenya	22-05-15	MT
Ind-Swift Ltd. Announces Demise of Jatendar Kumar Kakkar, Non-Executive Independent Director	22-03-26	CI
Ind-Swift Limited Announces the Resignation of Amrender Kumar Yadav as Company Secretary & Compliance Officer	22-02-26	CI

Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company. The Company operates in both domestic and export markets. It is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The Company is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. It operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The Company also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. It has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The Company also has five plants in India.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IND-SWIFT LIMITED	+28.80%	13.57M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.25%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.58%	244B
ROCHE HOLDING AG	+4.95%	234B
NOVARTIS AG	+16.20%	226B
AMGEN INC.	+14.63%	177B